Background: Hepatitis B e antigen (HBeAg) status is associated with clinical outcomes, and seroconversion of HBeAg is one of the treatment goals. In this study, we determined the association of on-treatment serum hepatitis B virus (HBV) DNA levels in HBeAg-positive chronic hepatitis B patients who were receiving entecavir (ETV) treatment. Methods: A retrospective cohort study was conducted involving 135 (78 male and 57 female; mean age, 42.3 ± 13 years) patients with HBeAgpositive chronic hepatitis B (CHB). Between August 2008 and March 2014, each patient was treated with ETV for at least 96 weeks, and their HBV DNA levels were evaluated every 3e6 months. HBeAg seroclearance at the 96 th week was defined as an absence of serum HBeAg within 96 weeks after ETV treatment. Univariate and multivariate logistic regression analysis was used to identify the predictors of 96 th week HBeAg seroclearance, and a multivariable model was constructed. Results: Among the 135 ETV-treated HBeAg-positive CHB patients, 37 patients achieved HBeAg seroclearance (Group 1), whereas 98 patients had persistent HBeAg-positive status (Group 2) at the 96 th week check-up. The baseline laboratory data was not significantly different between both the two groups. At the 24 th and 48 th weeks, there were significant differences between Group 1 and Group 2 in the percentage of patients with HBV DNA levels < 20 IU/mL [17/77 (22.1%) and 11/23 (47.8%), p ¼ 0.032; 45/89 (50.6%) and 26/35 (74.3%), p ¼ 0.028, respectively). Conclusion: Our study demonstrated that HBV DNA levels < 20 IU/mL at the 24 th and 48 th weeks could predict serum HBeAg loss in ETVtreated HBeAg-positive patients with CHB.
Introduction
Chronic hepatitis B (CHB) is a worldwide public health burden. CHB infection has been associated with an increased risk for developing cirrhosis and hepatocellular carcinoma. 1 In recent decades, there has been a dramatic and rapid progress in the treatment of CHB. 2, 3 The current treatment for CHB includes interferon-alfa, lamivudine, adefovir, entecavir (ETV), telbivudine, tenofovir, and pegylated interferon-a2a. There is evidence supporting the concept that antiviral therapy can ameliorate liver damage, progression of cirrhosis, and incidence of hepatocellular carcinoma. In patients with CHB infection, hepatitis B e antigen (HBeAg) is initially positive and accompanied by high levels of hepatitis B virus (HBV) DNA, which may persist for years or even decades. 7 HBeAg-positive immunotolerant patients with significant horizontal and vertical transmission carry a risk of contracting active chronic hepatitis and its complications. The current treatment options are not optimal. Pegylated interferon therapy offers sustained off-treatment responses in only a minority of patients. 8 Nucleoside analogs can suppress the on-treatment HBV DNA, improve liver histological lesions, reverse cirrhosis in the majority of cases, and improve survival rates.
9,10 Antiviral therapies may lead to sustained responses during therapy until the onset of treatment withdrawal. Thus, more commonly, a therapy must be continued to maintain responses achieved during the therapy. The shortterm goal of treatment for HBeAg-positive CHB is to achieve an initial response by HBeAg loss or seroconversion and/ or HBV DNA suppression, alanine aminotransferase (ALT) normalization, and prevention of hepatic decompensation. 11, 12 HBV DNA levels are associated with clinically significant pathological events, such as cirrhosis; therefore, changes in the serum levels of HBV DNA could determine a risk for hepatocellular carcinoma. 13, 14 For on-treatment follow-up, HBeAg loss/seroconversion is important during the nucleoside therapy for CHB patients. In China and other East Asian countries, HBeAg seroconversion was achieved in approximately 44e47% of patients after 4e5 years of lamivudine-based treatment. 15, 16 Under lamivudine treatment, studies from several Taiwan reports indicated that the rate of HBeAg seroconversion was associated with the pretreatment ALT level. 17, 18 ETV, a new guanosine nucleoside analog with specific activity against HBV DNA polymerase, represents a third agent within the nucleoside/nucleotide HBV polymerase inhibitor class. Compared with lamivudine and adefovir, ETV at 0.5 mg daily reportedly induces greater HBV DNA suppression, with HBV DNA becoming undetectable in 60e71% of HBeAgpositive patients and 88e90% of HBeAg-negative patients at 48e52 weeks. 3, 19 The HBeAg seroconversion rate was 31% by 2 nd year, and the HBeAg seroconversion rate in 141 HBeAgpositive patients was 23% from 96 th week to 240 th week.
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Among patients treated with ETV at 0.5 mg daily, 83e90% patients had undetectable HBV DNA, and 24e44% patients had HBeAg seroconversion at 3 rd year of the treatment.
20e22
ETV could suppress HBV DNA effectively, but the dynamic change of HBV DNA and corresponding HBeAg changes have not yet been clearly elucidated. Whether on-treatment followup HBV DNA is capable of predicting HBeAg seroconversion or seroclearance requires further investigation. To address these concerns, we conducted the present study to investigate whether on-treatment serum HBV DNA levels could predict HBeAg seroclearance during ETV-based therapy for HBeAg-positive CHB patients. In this retrospective, study patients were followed-up regularly every 12 weeks. Follow-ups included evaluations of serum HBV DNA levels at the 12 th week, 24 th week, and 48 th week since the ETV treatment initiation. The results of our study provide important information with respect to the prediction of HBeAg seroclearance during ETV therapy among HBeAg-positive CHB patients.
Methods

Patients
We conducted a retrospective cohort study by reviewing medical records and underwent a routine, regular treatment protocol for CHB patients. Between August 2008 and March 2014, a total of 135 (78 male and 57 female; mean age, 42.3 ± 13 years) patients with HBeAg-positive CHB who were treated with ETV for at least 96 weeks were included in this study. Patients were followed-up every 3 months and ALT, HBV DNA, and HBeAg status were routinely assessed every 3e6 months at Taichung Veterans General Hospital. Virological response is defined as a serum level of HBV DNA of < 20 IU/mL. 23 Patients were excluded in case of the following: (1) they had previously undergone antiviral treatment for hepatitis B; (2) they had HBeAg seroclearance within 24 weeks after ETV treatment; and (3) they were coinfected with the hepatitis C virus, hepatitis D virus, or human immunodeficiency virus (HIV). The study was approved by the Institutional Review Board of our institution (VGHTC CE16037B).
Outcome measurements
The primary endpoint of our analysis was HBeAg seroclearance, which was defined as negative serum HBeAg levels within 96 weeks of ETV treatment. ALT, bilirubin and HBV DNA levels were also routinely evaluated in our department.
Laboratory methods
HBV DNA was determined by real-time PCR assay (Roche Cobas TaqMan HBV Test). Hepatitis B surface antigen (HBsAg) and HBeAg and anti-HBe were determined by electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany).
Statistical analysis
Statistical tests were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were compared using the Chi-square test and Fisher's test, and continuous variables were expressed as mean and range and compared using the Student's t test or ManneWhitney U test.
Logistic regression was performed to analyze factors associated with HBeAg seroclearance at the 96 th week, and significant factors ( p < 0.05) in the univariate analysis were subjected to multivariate analysis to determine independent predictive factors. To avoid co-linearity of both parameters, HBV DNA levels at 24 th week and 48 th week were analyzed individually in multivariate analysis with age and sex adjustment. Statistical significance was defined as a p value of < 0.05.
Results
Patients' characteristics
Demographic data of ETV-treated patients with HBeAg seroclearance and without HBeAg seroclearance within 96 weeks is shown in Table 1 . A total of 135 HBeAg-positive CHB patients received ETV treatment. There were 37 (37.4%) ETV-treated patients with HBeAg seroclearance within 96 weeks (Group 1) and 98 (72.6%) ETV-treated patients without HBeAg seroclearance within 96 weeks (Group 2). There were no significant differences in age, sex, spleen size, and liver cirrhosis between the two groups. The baseline laboratory data, including platelet count, ALT, alkaline phosphatase, total bilirubin, anti-HBe, pretreatment serum HBV DNA, and alpha-fetoprotein (AFP) levels were not significantly different in both the groups (Table 1) .
Pretreatment HBV DNA levels could not predict HBeAg seroclearance within 96 weeks
There were no significant differences in pretreatment serum HBV DNA levels between ETV-treated patients with and without HBeAg seroclearance within 96 weeks. Pretreatment serum HBV DNA levels were expressed as log and are shown in Fig. 1 th week check-up, there were no significant differences between Group 1 and Group 2 in the proportion of patients with HBV DNA levels < 20 IU/mL [4/ 31 (12.9%) and 1/11 (9.1%), p ¼ 1.000, respectively]. Table 2 shows the associations of HBeAg seroclearance within 96 weeks and on-treatment serum HBV DNA levels. At the 24 th week check-up, there were significant differences between Group 1 and Group 2 in the proportion of patients with HBV DNA levels < 20 IU/mL [17/77 (22.1%) and 11/23 (47.8%), p ¼ 0.032, respectively]. At the 48 th week check-up, there were significant differences between the groups in the proportion of patients with HBV DNA levels < 20 IU/mL [45/89 (50.6%) and 26/35 (74.3%), p ¼ 0.028, respectively] (Fig. 2) . weeks. There were no significant differences between the HBeAg seroclearance group and non-HBeAg seroclearance group in the proportion of patients with HBV DNA levels < 20 IU/mL at the 12 th week, but significant differences were found at the 24 th week and 48 th week. Fisher's exact test. * p < 0.05, ** p < 0.01. Categorical data were expressed as n (%). Virological response within 48 weeks: serum HBV DNA < 20 IU/ml within 48 weeks.
Factors affecting HBeAg seroclearance within 96 weeks through univariate and multivariate analysis
Discussion
ETV is one of the major treatments for patients with hepatitis B infection owing to its superior ability to effectively suppress HBV DNA. However, HBeAg seroconversion or seroclearance is one of the major goals of nucleoside treatment; therefore, a clinical indicator for predicting the absence of HBeAg would be useful during the on-treatment follow-up. In this study, one-third of the patients who achieved HBeAg seroclearance under ETV treatment did so within 96 weeks. Our results demonstrated that HBV DNA levels < 20 IU/mL at the 24 th and 48 th week could predict HBeAg loss within 96 weeks in ETV-treated CHB patients.
A Chinese study involving lamivudine treatment for CHB demonstrated that CHB patients showed enhanced seroconversion rates, and up to two-thirds of patients with moderately elevated pretreatment ALT levels achieved HBeAg seroconversion after 3 years of therapy. 24 Wang et al 25 demonstrated that both baseline serum ALT levels > 5 times the upper normal limit and HBV DNA levels could predict HBeAg seroconversion. 25 However, the baseline serum ALT level was not a predictor for HBeAg seroconversion during ETV treatment in our study as well as in another study. 26 The reasons are possibly due to the variation of the baseline serum ALT level and the number of cases. A 4-year study reported that the baseline HBV DNA level was a significant factor associated with undetectable HBV DNA and HBeAg seroclearance at 1e3 years. 27 Thus, undetectable HBV DNA could be considered as another predicting factor in HBeAg serological change. Our data indicated that HBV DNA levels < 20 IU/mL at both 24 th week and 48 th week were positively associated with favorable serological change in CHB patients with ETV treatment. This finding is consistent with previous studies. 26, 28 Additional predictors for HBeAg seroconversion during treatment have been studied, and serum HBV RNA levels may serve as a novel tool for the prediction of serological response during polymerase inhibitor treatment in HBeAg-positive patients. 29 However, currently it is not commonly used in routine follow-up for CHB treatment. Among HBeAg-positive CHB patients, nucleoside could significantly improve the rates of histologic, virological, and biochemical profiles. Our results are similar to those of previous reports. Without significant and rapid HBV DNA suppression, ETV-treated CHB patients possibly need a longer treatment duration in order to obtain histological and serological benefits. 12 HBeAg-positive patients older than 40 years with persistently high or high to normal ALT levels may be diagnosed with significant hepatic necroinflammation or fibrosis. 30 During treatment, the clinical significance of timing of HBeAg loss or seroconversion remains unclear. However, a longer duration of a HBeAg-positive status may indicate ongoing hepatic inflammation. Quantitative HBsAg (qHBsAg) levels have the potential for a follow-up treatment response in CHB for the prediction of a response to interferon-alpha. In HBeAgpositive patients with ETV therapy, patients with HBeAg seroclearance or seroconversion showed an early decline in their HBsAg levels.
31e34 However, the baseline HBsAg level and decline at 12 th week or 24 th week could not predict HBeAg seroconversion at 2 years. 35 In the present study, we did not routinely check qHBsAg during ETV treatment for CHB. Thus, we could not compare qHBsAg or HBV DNA dynamics for any prediction of HBeAg seroconversion.
The ideal treatment end-point is sustained HBsAg loss with or without anti-HBs seroconversion in HBeAg-positive and HBeAg-negative patients. Actually, the duration of ETV treatment for HBeAg positive CHB may be up to 240 weeks. 12 A duration of consolidation therapy after HBeAg seroconversion is indicated. 36 Our results showed that HBV DNA levels < 20 IU/mL at the 24 th week could early predict the likelihood of HBeAg loss.
Our study had some limitations. First, in this singleinstitution study, the number of patients enrolled was limited. Second, HBeAg-positive hepatitis B patients under treatment are regularly followed-up by protocol. However, as a retrospective study, there still remained portions of missing data from our patients. Third, compliance of medication prescription schedules is important in a pharmacological study and follow-up. There are some difficulties encountered when attempting to confirm compliance of our patients by strictly reviewing medical records alone. We had 18 patients who developed virological breakthrough under follow-up, which is mostly due to poor compliance; therefore, we assumed that these patients in our study could achieve 90% compliance. Fourth, we considered that HBeAg seroclearance within 6 months of ETV was possibly due to the efficacy of antiviral therapy or spontaneous HBeAg seroclearance. We excluded patients with HBeAg seroclearance within 6 months, which might introduce a selection bias due to including only later HBeAg seroclearance patients. This could be the reason why this study failed to investigate the HBV DNA at 12 th week when predicting HBeAg seroclearance within 96 weeks. Besides, further studies will be warranted to understand the association of the early dynamic change of HBV DNA and serologic response in HBeAg-positive patients.
Our study demonstrated that HBV DNA levels < 20 IU/mL at the 24 th week and 48 th week could predict serum HBeAg loss in ETV-treated HBeAg-positive CHB patients. This finding indicates that ETV-treated HBeAg-positive CHB patients are less likely to achieve HBeAg seroclearance within 96 weeks if they did not have an HBV DNA level of < 20 IU/ mL at the 24 th or 48 th week.
